[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"interstitial-lung-abnormalities\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:interstitial-lung-abnormalities":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100608466","phase-3-a-study-to-test-whether-nerandomilast-can-help-slow-down-changes-in-the-lung-in-people-with-a-family-history-of-pulmonary-fibrosis-100608466",false,"NCT07201922","A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis","A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)","Inclusion Criteria:\n\n* Individuals ≥40 years of age at the time of first signed informed consent at Visit 1a\n* Participants must have at least 1 first-degree relative (biological parent, sibling, or child) with confirmed pulmonary fibrosis (idiopathic pulmonary fibrosis \\[IPF\\], idiopathic nonspecific interstitial pneumonia \\[NSIP\\], and\u002For pulmonary fibrosis due to known genetic cause \\[e.g. short telomere syndrome, mucin 5B (MUC5B) mutation, surfactant protein mutations\\])\n* High resolution computed tomography (HRCT) scan with evidence of interstitial lung abnormalities involving at least 5% of a single lung zone or interstitial lung disease (ILD), based on central evaluation\n* Forced vital capacity (FVC) ≥80% of predicted normal at Visit 1b\n* Diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin ≥70% of predicted normal at Visit 1b Further inclusion criteria apply.\n\nExclusion Criteria:\n\n* Prior known pulmonary fibrosis that, in the opinion of the Investigator, requires treatment with approved therapies\n* Prebronchodilator forced expiratory volume in 1 second (FEV1)\u002FFVC \\\u003C0.7 at Visit 1b\n* HRCT findings consistent with probable or definite usual interstitial pneumonia (UIP) pattern\n* Any medical condition that is known to predispose to the development of pulmonary fibrosis (e.g. known connective tissue disease)\n* Prior or current use of nerandomilast, nintedanib, or pirfenidone Further exclusion criteria apply.","ALL","40 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe. People can join if a lung scan shows early changes in the lung, called interstitial lung abnormalities, which may lead to lung scarring. People with family members who have pulmonary fibrosis are more likely to develop it themselves. That is why it is important to check early for lung changes and find ways to prevent the condition from getting worse. The purpose of this study is to find out whether a medicine called nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis.\n\nParticipants are put into one of 2 groups randomly, which means the group is chosen by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet twice a day for about 2 to 3 years. There is a 3 out of 5 chance that participants will receive nerandomilast instead of the placebo.\n\nParticipants are in the study for about 2 to 3 years. Participants visit the study site multiple times: more frequently during the first 2 years (about every 3 months), and then every 6 months thereafter. In the 3rd year, participants also have phone calls with the site staff every 3 months.\n\nDoctors regularly test lung function and take chest scans to see if the treatment works. The results are compared between the 2 groups to see if nerandomilast helps. The doctors also check participants' health and take note of any unwanted effects.",[26,27,28],"Familial Pulmonary Fibrosis","Interstitial Lung Abnormalities","Interstitial Lung Diseases","RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":33},"2026-02-10",{"date":37,"type":20},"2029-05-23",{"name":39,"class":40},"Boehringer Ingelheim","INDUSTRY",56,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100594755","study-on-screening-strategies-for-interstitial-lung-abnormalities-and-airway-lesions-100594755","NCT07023575","Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions","SSILA","Inclusion Criteria:\n\n* Underwent chest CT examination between January 1, 2017 and December 31, 2024\n* Age 18 years or older at the time of examination\n\nExclusion Criteria:\n\n\\- Missing or incomplete key demographic or imaging information (e.g., missing date of examination, sex, age, or CT report)",true,{"count":51,"type":20},100000,"OBSERVATIONAL","The goal of this observational study is to learn about the comorbidity patterns of interstitial and airway abnormalities in adults undergoing health examinations in China. The main questions it aims to answer are:\n\nHow do early interstitial lung abnormalities progress to comorbid interstitial and airway diseases? What are the key factors associated with this progression?\n\nParticipants undergoing routine health examinations will be assessed for interstitial and airway abnormalities based on imaging and clinical data. Longitudinal follow-up will be used to evaluate disease progression and identify associated risk factors.",[27],[56],"interstitial lung abnormalities","NOT_YET_RECRUITING","2025-06-15",{"date":60,"type":33},"2025-06-17",{"date":62,"type":20},"2025-08-01",{"date":64,"type":20},"2028-11-30",{"name":66,"class":67},"China-Japan Friendship Hospital","OTHER",10]